INVESTOR

PRESS RELEASES


Press ReleaseRelease DateDownload
TherapeuticsMD Announces Q2 2014 Financial Results 8/6/2014
THERAPEUTICSMD TO HOLD SECOND QUARTER 2014 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST ON AUGUST 6 8/1/2014
THERAPEUTICSMD ANNOUNCES PRICING OF OFFERING OF COMMON STOCK 7/30/2014
TXMD Announces $40 Million Offering of Common Stock 7/29/2014
TXMD to Present at JMP HealthCare Conference 6/17/2014
TXMD Announces 2014 Investor Day Webcast on June 16 6/10/2014
TherapeuticsMD Announces Release of RediChew and Prena1 Chew 5/28/2014
TXMD Announces 2014 Investor Day 5/27/2014
TXMD to Present at Jefferies 2014 HealthCare Conference 5/22/2014
THERAPEUTICSMD REPORTS FIRST QUARTER 2014 RESULTS 5/5/2014
THERAPEUTICSMD TO PRESENT THE DESIGN OF ITS REPLENISH TRIAL AT THE IMS 14th WORLD CONGRESS 5/1/2014
TXMD to Present at Bank of America Merrill Lynch 2014 Health Care Conference 4/29/2014
THERAPEUTICSMD TO HOST CONFERENCE CALL AND LIVE AUDIO WEBCAST TO DISCLOSE Q1 FINANCIAL RESULTS 4/25/2014
THERAPEUTICSMD REPORTS POSITIVE RESULTS OF RABBIT IRRITATION STUDY 4/7/2014
BOCAGREENMD LAUNCHES PRENA1 PEARL 4/6/2014
THERAPEUTICSMD ANNOUNCES PRICING OF SECONDARY OFFERING 3/20/2014
VITAMEDMD LAUNCHES VITAPEARL 3/19/2014
TXMD ANNOUNCES LAUNCH OF SECONDARY OFFERING 3/18/2014
THERAPEUTICSMD REPORTS FOURTH QUARTER AND FULL-YEAR 2013 RESULTS 3/3/2014
TXMD Conference Call to Disclose 2013 Year-End Results 2/25/2014
TherapeuticsMD to Present at Cowen & Co. 34th Annual Healthcare Conference 2/25/2014
THERAPEUTICSMD REPORTS POSITIVE PK STUDY RESULTS FOR ITS ESTRADIOL VAGICAP™ (TX 12-004-HR) 1/28/2014
THERAPEUTICSMD INITIATES PHASE 3 CLINICAL TRIAL OF ITS PROGESTERONE CANDIDATE (TX 12-002-HR) FOR TREATMENT OF SECONDARY AMENORRHEA 1/24/2014
THERAPEUTICSMD ANNOUNCES ISSUANCE OF U.S. PATENT COVERING TX 12-001-HR 1/22/2014
TherapeuticsMD announces 50th site for Phase 3 Clinical Trial of TX 12-001HR 1/6/2014
TherapeuticsMD names Randall S. Stanicky to Board of Directors 12/18/2013
TherapeuticsMD receives notice of allowance for patient covering platform technology... 12/9/2013
TherapeuticsMD appoints Joel S. Krasnow, M.D. as Chief Scientific Officer 12/4/2013
TherapeuticsMD to present at 25th annual Piper Jaffray Healthcare Conference 11/22/2013
TherapeuticsMD Applauds Congressional Leadership on Passage of Drug Quality and Security Act 11/19/2013
TherapeuticsMD reports third quarter 2013 financial results 11/4/2013
TherapeuticsMD appoints Sebastian Mirkin, M.D. as Chief Medical Officer 10/23/2013
VVA Phase 1 Results 10/22/2013
TherapeuticsMD Third Quarter Results Conference Call 10/21/2013
TherapeuticsMD, Inc. poster wins first-place prize at the North American Menopause Society 2013 Annual Meeting 10/18/2013
Phase 1 data on first oral combination 17β-Estradiol and Progesterone capsule being developed for FDA review 10/9/2013
TherapeuticsMD to present at 12th Annual BIO Investor Forum 10/4/2013
TherapeuticsMD announces pricing of offering of common stock 9/25/2013
TherapeuticsMD begins patient enrollment in pivotal phase 3 clinical trial of TX 12-001-HR 9/5/2013
TherapeuticsMD to present at STIFEL NICOLAUS 2013 Healthcare Conference 8/29/2013
TherapeuticsMD Initiates Phase 1 Study Of Estradiol Vagicap™ 8/12/2013
TherapeuticsMD Reports 2nd Quarter 2013 Financial Results 8/6/2013
TherapeuticsMD, Inc. Added to 2013 Russell Indexes 7/1/2013
TherapeuticsMD to Present at JMP Securities Healthcare Conference 6/26/2013
TherapeuticsMD Investigational New Drug Filing Accepted By FDA 6/14/2013
TherapeuticsMD to Ring Opening Bell at NYSE 6/11/2013
TherapeuticsMD To Present Jefferies Conference 5/28/2013
TherapeuticsMD elects Jules A. Musing to Board of Directors 5/16/2013
TherapeuticsMD reports first quarter 2013 financial results 5/8/2013
TherapeuticsMD Announces Trading of its Common Stock on the NYSE MKT under symbol "TXMD" 4/19/2013
TherapeuticsMD Announces Pricing of Public Offering of Common Stock 3/15/2013
TherapeuticsMD Announces $50,000,000 Proposed Public Offering of Common Stock 3/7/2013
BocaGreenMD, Inc. Launches Line of Generic Prescription Prenatal Multivitamins 11/1/2012
TherapeuticsMD, Inc. Announces $8.5 Million Private Placement 9/26/2012
TherapeuticsMD, Inc. Has IND Filing Accepted By FDA 8/7/2012
TherapeuticsMD, Inc. Launches vitaMedMD™ Iron 21/7, a Unique, Patient-friendly Iron Supplement 7/17/2012
TherapeuticsMD, Inc. Announces Plans in Hormone Therapy That Concur with the Recent Joint Statement From NAMS, ASRM and the Endocrine Society 7/10/2012
TherapeuticsMD, Inc. Files for Two Additional Patents on Prescription Products For Treatment of Menopausal Symptoms & Related Conditions 6/21/2012
Tommy G. Thompson, Former U.S. Secretary of Health and Human Services, Joins TherapeuticsMD, Inc. as Chairman 5/16/2012
TherapeuticsMD, Inc. Launches VitaMedMD RediChew Rx, The First Daily Chewable Prescription Prenatal Vitamin with Quatrefolic 5/10/2012
TherapeuticsMD, Inc. Launches VitaMedMD One Rx, The First Daily One Pill Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA 4/9/2012
TherapeuticsMD, Inc. Elects Four Additional Directors 3/2/2012
TherapeuticsMD, Inc. Launches VitaMedMD Plus Rx, The First Prescription Prenatal Vitamin with Quatrefolic and Plant-Based DHA 3/2/2012
TherapeuticsMD, Inc. Launches Its First Prescription Prenatal Vitamin on March 1, 2012 2/7/2012
TherapeuticsMD, Inc. Acquires VitaMedMD, LLC 10/5/2011